Drug intelligence / Profile preview

NAFB-002

Development stage: Discontinued
Lead developer: Digna Biotech
Modality: Small Molecules, Peptides

Overview

NAFB-002 is a therapeutic candidate developed by the now-dissolved Spanish biotechnology company Digna Biotech. It was designed as a small molecule or peptide antagonist targeting transforming growth factor beta 1 (TGF-β1), a cytokine that plays a central role in the pathogenesis of tissue fibrosis by promoting fibroblast activation and the excessive production of extracellular matrix. NAFB-002 was primarily investigated for the treatment of pulmonary fibrosis. Following the dissolution of Digna Biotech, the development of NAFB-002 was halted, and the drug is currently classified as discontinued.

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on NAFB-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAFB-002.

Explore the full profile